About
Immunotherapy Solutions for GI Cancers
TanoMed is developing immune cell-targeted nanodelivery solutions designed to improve therapeutic efficacy by triggering tumor destruction following T- and B-cell priming. TanoMeds precision immuno-oncology therapy is based on a novel dendritic cell-targeted nano-immunomodulator platform that combines antigen-carrying capacity with in vivo targeting and modulation of DC function, thereby expanding the host antitumor specific T-effector phenotype and improving sensitivity and long-term tumor recognition.
Identity
| Name | TanoMed |
|---|---|
| Slug | tanomed |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4PP4gq8JDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Feb 2022 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Herzliya |
| HQ address | Herzliya, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B2C
Tags
cancerimmunotherapypharma-companiesoncologynanotechnologygastroenterologybiotechnologycancer-therapypersonalized-medicinestealthmode
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}